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Introduction:
Chemokines, or chemotatic cytokines, are are a family of glycoproteins that range
from around 70 to 90 amino acids in length and have a mass of about 8 to 10 kDa.  There
are four classes of chemokines that are divided according the order of their two terminal
cysteine residues (CC, CXC, CX3C, and C).  These small secreted proteins bind to their
cognate receptors which are membrane bound proteins. Chemokine receptors are part of a
class of proteins named “G-protein coupled receptors” (GPCRs).  These transmembrane
proteins have seven transmembrane helices and are linked on the interior of the cell to g-
proteins.  CPCRs bind their cognate ligands on the exterior surface of the cell membrane
and transfer the signal to the interior space, thereby signaling a cascade via the G-proteins.
Chemokines attract, activate and regulate tissue infiltration by leukocytes.  This is
a key component of the inflammatory response.  Chemokines are expressed in inflamed
tissue, and are ligands for chemokine receptors, which are expressed on the membranes of
leukocytes 1.   The inflammatory response includes a change in the expression level of
certain chemokines in the leukocytes.  Chemokine receptors are also required for the
infection of Leukocytes by the human immunodeficiency virus (HIV-1) 4.  These
interactions also play a role in the inflammation of the bronchial tubes in an asthmatic
episode 8.  The elucidation of the interaction of chemokines and their cognate receptors
would be beneficial in the treatment of both of these diseases as wells as providing insight
into the mechanism of tissue inflammation.
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Background:
Eotaxin , a CC chemokine,  is  a selective stimulus for eosinophil leukocytes.  This
chemokine induces the migration of eosinophils in vitro and eosinophil accumulation in
vivo 5,7.  Eotaxin is an agonist of the CC chemokine receptor 3 (CCR3) the most abundant
chemokine receptor on eosinophils 3.  Binding of Eotaxin to CCR3 has been linked to
allergic asthma and allergic rhinitis 7.
The determination of the interaction of Eotaxin with CCR3 has been difficult to
elucidate, because CCR3 in an integral membrane protein which makes it hard to isolate
and crystallize 10.   To overcome this barrier a soluble protein that mimics the ligand
binding elements of GPCRs was designed, prepared, and characterized.  Named CROSS
(chemokine receptor elements on a soluble scaffold), these proteins consisted of two of
the ligand binding elements of CCR3, on the surface of the B1 domain of Streptococcal
protein G (Fig. 1) 2.  The B1 domain is small thermostable (~6 kD, ?Gunfolding = 28 kJ/mole
at 30oC) 6.  Previous work reported the synthesis of three CROSS proteins named
CROSS1-CROSS7, these CROSS proteins only had the N-terminal and E3 segments of
CCR3.  The most favorable CROSS protein was CROSS5, which incorporated the Mayo
hydrophobic core, a hyperstable B1 domain mutant, and a disulfide bond between ?-
strands ?1 and  ?2 .  CROSS5 was found to have a KD equilibrium constant of 2.9 ± 0.8 µM
2 for binding to eotaxin.
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It has been postulated that the low affinity of CROSS5 for Eotaxin is a result of the
exclusion of the E1 and E2 regions of CCR3 from the CROSS proteins.  To determine the
effect of the E1 and E2 domains of CCR3 in binding Eotaxin, it was decided that CROSS
proteins that contained both the E1 and E2 regions of CCR3 should be synthesized and
their binding affinities measured.  The scaffold for these proteins is the single-chain variant
of ROP developed by Lynn Regan and colleagues.  Cecelia Cheng cloned, expressed and
purified twelve CROSS proteins with different combinations of the E1 and E2 domains as
well as replacing the native Cys in the E1 or E2 domain with a Ser residue.  The Goal of
this project is to determine whether the soluble protein containing the E1 and E2 elements
of CCR3, ROPS55 CCR3E1C-E2C binds to the chemokine Eotaxin, by utilizing isothermal
titration calorimetry (ITC), and to determine KD, stochiometry, and thermodynamic values
??H, ?S, ?G) for binding.
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Results and Discussion:
Preparation and Purification of CROSS
ROPS55 CCR3E1C-E2C  had previously been cloned, expressed and purified by
Cecelia Cheng.  The protein was re-lyophilized to remove condensation.
Preparation and Purification of Eotaxin
Eotaxin of unknown purity was available from Michael Goodman.  The protein
solution was condensed and purified by HPLC using a C4 column, in acetonitrile buffers.
SDS page electrophoresis was used to determine the purity of Eotaxin fractions.
ITC Experiment
 Eotaxin and ROPS55 CCR3E1C-E2C were dialyzed against 50mM MOPS buffer at pH
7.  After dialysis the concentration of each protein was determined by using their
respective OD280.  An aliquot of Eotaxin  was then diluted to give 300µL of a 500 µM
solution.  An aliquot ROPS55 CCR3E1C-E2C was diluted to give 2.0 mL of  a 10 µM
solution.  ITC experiments were to be carried out on a Microcal VP-ITC instrument.  All
solutions were thouroghly degassed before ITC was carried out.  Eotaxin was injected
into the calorimeter well and ROPS55 CCR3E1C-E2C was to be drawn into the syringe, but
when the ROP solution was drawn into a Hamiliton syringe it was noticed that the protein
was aggregating and precipitating out of solution.  Several attempts to soluablizie the
protein failed.  The stock of ROPS55 CCR3E1C-E2C had been depleted, therefore ITC
experiments were postponed until more ROPS55 CCR3E1C-E2C could be expressed and
purified.
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Expression and Purification of ROPS55 CCR3E1C-E2C
Expression and purification was performed following the protocol set for by Ceclia
Cheng for expression of ROPS55 CCR3E1C-E2C.  Expression was performed using BL21
cells, and a four liter growth was performed.  Upon purification none of the desired
protein was seen.  One possible explanation is that it crashed off the column immedialty
upon loading the column and was lost.
Experimental:
Preperation and Puification of ROPS55 CCR3E1C-E2C
ROPS55 CCR3E1C-E2C was cloned, expressed and purified by Ceclia Cheng.  The
lyophilized was dissolved in 1.0 mL of H2O and the OD280 used to determine the
concentration.
Preperation and Purification of Eotaxin
  Eotaxin was cloned, expressed and purified by Michael Goodman.  Seventeen
milliliters of Eotaxin solution was concentrated to approximately 5 mL.  The solution was
purified in four aliquots using a C4 column on a HPLC apparatus.  The first aliquot was
2.0 mL, but overloaded the detector.  SDS page gel electrophoresis was used to determine
which fractions contained the Eotaxin.  Three subsequent aliquots of 1 mL apiece were
purified on the C4 column.  SDS gel electorphoresis was used to confirm purification.
The fractions from each purification that contained Eotaxin was pooled and then
concentrated to 2.0 mL and the concetration determined using it OD280.
ITC
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The Eotaxin and ROPS55 CCR3E1C-E2C solutions were then dialyzed for 24 hours in
2.0L of 50mM MOPS buffer at pH 7, with 0.02% NaN3 added to prevent bacteria growth.
After dialysis the concentration of both solutions was again determined using their OD280.
An aliquot of Eotaxin was diluted with the dialysis buffer to give 300 µL of 500 µM
solution.  An aliquot of ROPS55 CCR3E1C-E2C was diluted with dialysis buffer to give 2.0
mL of 10 µM solution.  Both solutions were degassed by stirring  for two hours under
vacuum.  The Eotaxin solution was transferred to the ITC reaction well, and the ROP
solution was to be titrated in.  Aggregation and precipitation of the ROP prevented the
completion of the ITC experiment.
Expression and Purification of ROPS55 CCR3E1C-E2C
  Fifty millilites of  LB was inoculated with one colony of Rop, and 50 µL of Kan.
was added. The starter culture was then transferred to 500 mL flasks and 500 uL of Kan.
added.  When the OD280 reached 0.600 the cells were induced with 5 mL of 100 mM
IPTG. After 6.5 hours the cells were spun down at 8 K for 10 min. Cells were
resuspended in 20 mL ROP lysis buffer (Table 1).  One hundred and twenty mirco liters of
50 mM lysomzyme and PMSF was added and then incubated on ice for 10 min.  The cells
were sonicated five times with a large tip, 30 sec/1 min rest cycles at level 4.5.  The cells
were then spun down at 17 K for 20 min. The pellets were resuspended in resuspension
solution (Table 1). The resuspended pellets were incubated for one hour on ice, then spun
down a second time at 17 K for 20 min.  After centrifugation the pellets were resuspended
in resuspension solution.  Supernatant was dialyzed in 4 L of refolding buffer (Table 2) for
12 hours at room temperature.  The solution was then transferred and dialyzed in refolding
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buffer B (Table 1) for 12 hours at room temperature.  Then the solution was transferred
and dialyzed into the final buffer (Table 1) for 12 hours at room temperature.  After final
dialysis the solution was concentrated to 100 mL.  Final solution was purified on a FPLC
Q column.  No product was seen.
Solution
ROP Lysis Buffer pH 7.4 50 mM Tris-HCl,  2 mM EDTA,  10mM CaCl2,
0.5 mM DTT
Resuspension Solution pH 4.0 10 mM Tris-HCl,  8 M Urea,
100 mM NaH2PO4
Refolding Buffer A pH 8 50 mM Tris-HCl,  50 mM glycine,
 500 mM NaCl,  3 M Urea,
 0.4 mM oxidized glutathione,
 4.0 mM reduced glutathione
Refolding Buffer B pH 8 50 mM Tris-HCl,  50 mM glycine,
500 mM NaCl, 1 M Urea,
0.5 mM oxidized glutathione,
2.4 mM reduced glutathione
Final Buffer pH 8 20 mM Tris-HCl,  150 mM NaCl
Table 1:  Solutions used in Expression of ROPS55 CCR3E1C-E2C.
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